- Home
- SYRE vs XNCR Comparison
SYRE vs XNCR Comparison
Compare SYRE & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRE
- XNCR
- Stock Information
- Founded
- SYRE 2013
- XNCR 1997
- Country
- SYRE United States
- XNCR United States
- Employees
- SYRE N/A
- XNCR N/A
- Industry
- SYRE Biotechnology: Pharmaceutical Preparations
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- SYRE Health Care
- XNCR Health Care
- Exchange
- SYRE Nasdaq
- XNCR Nasdaq
- Market Cap
- SYRE 1.1B
- XNCR 1.1B
- IPO Year
- SYRE 2016
- XNCR 2013
- Fundamental
- Price
- SYRE $23.71
- XNCR $14.91
- Analyst Decision
- SYRE Strong Buy
- XNCR Buy
- Analyst Count
- SYRE 5
- XNCR 11
- Target Price
- SYRE $55.75
- XNCR $23.50
- AVG Volume (30 Days)
- SYRE 741.8K
- XNCR 1.2M
- Earning Date
- SYRE 11-04-2025
- XNCR 11-05-2025
- Dividend Yield
- SYRE N/A
- XNCR N/A
- EPS Growth
- SYRE N/A
- XNCR N/A
- EPS
- SYRE N/A
- XNCR N/A
- Revenue
- SYRE N/A
- XNCR $150,132,000.00
- Revenue This Year
- SYRE N/A
- XNCR $22.09
- Revenue Next Year
- SYRE N/A
- XNCR N/A
- P/E Ratio
- SYRE N/A
- XNCR N/A
- Revenue Growth
- SYRE N/A
- XNCR 38.16
- 52 Week Low
- SYRE $10.91
- XNCR $6.92
- 52 Week High
- SYRE $33.47
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- SYRE 60.31
- XNCR 59.08
- Support Level
- SYRE $21.63
- XNCR $13.12
- Resistance Level
- SYRE $24.19
- XNCR $15.29
- Average True Range (ATR)
- SYRE 1.33
- XNCR 1.01
- MACD
- SYRE -0.26
- XNCR -0.09
- Stochastic Oscillator
- SYRE 67.01
- XNCR 76.85
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.